Ethinylestradiol + Progesterone Injection
- Packing: 1 Ml Ampoule, 1 ml PFS.
- Available Strength : 0.02 Mg/Ml + 12.5 Mg/Ml
Description
Product Description: Ethinylestradiol + Progesterone Injection is a combination hormonal medication containing ethinylestradiol, a synthetic estrogen, and progesterone, a synthetic form of the hormone progesterone. This injectable formulation provides a convenient option for hormonal therapy, offering both estrogen and progestin components in a single injection.
Indications and Usage: Ethinylestradiol + Progesterone Injection is indicated for various therapeutic purposes, including hormone replacement therapy (HRT) in postmenopausal women, management of menopausal symptoms, contraception, and treatment of certain gynecological conditions such as abnormal uterine bleeding and endometriosis.
Dosage and Administration: The dosage of Ethinylestradiol + Progesterone Injection varies depending on the indication, patient's age, and medical history. It is typically administered via intramuscular injection according to a prescribed dosing schedule determined by a healthcare provider. Dosage adjustments may be necessary based on individual patient response.
Dosage Forms and Strengths: Ethinylestradiol + Progesterone Injection is available as a sterile solution in vials or pre-filled syringes. Each milliliter of the solution contains a specific amount of ethinylestradiol and progesterone, typically ranging from 5 mg/mL to 10 mg/mL for each hormone component.
Contraindications: Ethinylestradiol + Progesterone Injection is contraindicated in pregnant women, women with a history of breast cancer, liver dysfunction, thromboembolic disorders, and hypersensitivity to ethinylestradiol, progesterone, or any of the components of the formulation. It should not be used in women with uncontrolled hypertension or certain cardiovascular conditions.
Warnings and Precautions: Before initiating therapy with Ethinylestradiol + Progesterone Injection, healthcare providers should evaluate patients for cardiovascular risk factors, including hypertension, diabetes, smoking, and obesity. Patients should be monitored regularly for signs of thromboembolic events, breast abnormalities, and other adverse effects associated with estrogen-progestin therapy.
Adverse Reactions/Side Effects: Common adverse reactions associated with Ethinylestradiol + Progesterone Injection include nausea, breast tenderness, headache, breakthrough bleeding, and mood changes. Other potential side effects may include fluid retention, weight gain, and allergic reactions.
Drug Interactions: Ethinylestradiol + Progesterone Injection may interact with other medications, including corticosteroids, anticonvulsants, anticoagulants, and herbal supplements. Healthcare providers should carefully evaluate patients for potential drug interactions before initiating therapy.
Use In Specific Populations Description: Ethinylestradiol + Progesterone Injection is not recommended for use in pregnant women or women who are breastfeeding. It should be used with caution in women with a history of cardiovascular disease, liver dysfunction, or other medical conditions that may increase the risk of adverse effects.
How Supplied/Storage and Handling: Ethinylestradiol + Progesterone Injection is supplied as a sterile solution in vials or pre-filled syringes. It should be stored at controlled room temperature, protected from light and moisture. Unused portions should be discarded according to local regulations for biohazardous waste disposal.
